Kala Pharmaceuticals Inc (NASDAQ:KALA) – Wedbush cut their FY2020 earnings per share (EPS) estimates for Kala Pharmaceuticals in a report issued on Tuesday. Wedbush analyst L. Moussatos now forecasts that the company will post earnings of $2.73 per share for the year, down from their prior estimate of $2.78. Wedbush currently has a “Buy” rating and a $46.00 target price on the stock. Wedbush also issued estimates for Kala Pharmaceuticals’ FY2021 earnings at $8.87 EPS.

Kala Pharmaceuticals (NASDAQ:KALA) last issued its quarterly earnings data on Tuesday, November 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.14).

KALA has been the subject of a number of other reports. Zacks Investment Research downgraded shares of Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. J P Morgan Chase & Co set a $35.00 price objective on shares of Kala Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, November 19th. Wells Fargo & Company assumed coverage on shares of Kala Pharmaceuticals in a research note on Monday, August 14th. They issued an “outperform” rating and a $24.00 target price on the stock. Oppenheimer assumed coverage on shares of Kala Pharmaceuticals in a research note on Tuesday, August 15th. They issued an “outperform” rating and a $46.00 target price on the stock. Finally, Bank of America assumed coverage on shares of Kala Pharmaceuticals in a research note on Monday, August 14th. They issued a “buy” rating and a $33.00 target price on the stock. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $36.80.

Shares of Kala Pharmaceuticals (NASDAQ KALA) traded down $0.67 during mid-day trading on Wednesday, reaching $17.53. 80,536 shares of the company’s stock were exchanged, compared to its average volume of 189,090. Kala Pharmaceuticals has a twelve month low of $13.51 and a twelve month high of $26.75. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Kala Pharmaceuticals during the 3rd quarter valued at approximately $105,000. American International Group Inc. purchased a new stake in shares of Kala Pharmaceuticals during the 3rd quarter valued at approximately $122,000. Susquehanna International Group LLP purchased a new stake in shares of Kala Pharmaceuticals during the 3rd quarter valued at approximately $222,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Kala Pharmaceuticals during the 3rd quarter valued at approximately $228,000. Finally, California State Teachers Retirement System purchased a new stake in shares of Kala Pharmaceuticals during the 3rd quarter valued at approximately $301,000. Hedge funds and other institutional investors own 62.96% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/06/wedbush-comments-on-kala-pharmaceuticals-incs-fy2020-earnings-kala.html.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Receive News & Ratings for Kala Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.